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Abstract
Percutaneous cholecystostomy is a treatment for acute calculous cholecystitis used in patients where surgery is high risk or
challenging either to allow for surgical optimisation or as definitive treatment. In this case series we compare the outcomes of
a transhepatic versus transperitoneal approach in patients undergoing percutaneous cholecystostomy for acute calculous
cholecystitis. A retrospective review of patients from 2014 to 2019 was conducted and included demographics, percuta-
neous cholecystostomy route, complications and outcome. Fifty-one patients were included. Percutaneous cholecystostomy
was placed transhepatically in 15 cases; transperitoneal in 30 cases; 6 cases had undetermined route. The transhepatic cohort
had 43.5% fewer readmissions due to biliary sepsis, 32.5% fewer drain-related complications, and were less likely to require
further treatment (32.5% reduction) compared to the transperitoneal cohort. In our experience, the transhepatic route is
preferred due to fewer complications, fewer readmissions and a reduction in the need for further treatment.
INTRODUCTION
Acute cholecystitis is a frequent cause of emergency general
surgical admission, with up to 95% of cases attributed to gall-
stone disease. Given increasing age is a strong risk factor for gall-
stone disease, and with an ageing population, acute calculous
cholecystitis (ACC) will likely represent an increasing burden on
Western healthcare systems for the foreseeable future [1].
Cholecystectomy is widely regarded as the best treatment
for ACC in patients who are deemed fit for surgery. However,
patients at high risk for surgery or in those whose protracted
illness makes surgery challenging due to significant inflamma-
tion, cholecystectomy can lead to significant morbidity and mor-
tality [2]. Percutaneous cholecystostomy (PC), either as a bridging
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measure to surgery or as a definitive treatment, is a valuable
treatment option in this subset of patients. International guide-
lines recommend that it should be considered in patients with
moderate or severe ACC, those with severe systemic disease, or
patients who have failed medical therapy [3, 4].
Although surgical cholecystostomy was first published in
1867 [5], PC was first reported as a treatment for obstructive
jaundice in 1979 [6] and later as a treatment for gallbladder
empyema in 1980 [7]. PC is an image-guided, radiological proce-
dure, directly decompressing the infected gallbladder contents,
thereby reducing inflammation and improving patients’ general
condition [8]. It has been shown to be safe in patients with
multiple comorbidities, with a reported mortality rate of 12% and
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a complication rate of 4% in patients specifically with ACC [9].
PC can be placed via a transhepatic (TH) or transperitoneal (TP)
route. With only limited series existing in the literature showing
similar outcomes for both techniques, the optimal choice of PC
route remains a much debated topic [10, 11].
We sought to compare the outcomes for patients undergoing
PC for ACC via a TH or TP approach in a tertiary centre over a 5-
year period. The outcome measures chosen included the need
for further hospital admission due to biliary sepsis or drain-
related complications, endoscopic retrograde cholangiopancre-




Patients undergoing PC for ACC at a UK tertiary hospital between
November 2014 and June 2019 were retrospectively identified.
Patients were identified from a search of the hospital’s elec-
tronic health records database using the keywords ‘percuta-
neous drainage of gallbladder’, ‘cholecystostomy during an asso-
ciated admission’ and ‘ultrasound guided drain of abdominal
abscess’. To ensure inclusion of all patients, a search of the rele-
vant current procedural terminology codes used at our hospital
for PC placement was performed. Patient’s records were then
reviewed to exclude any patients that underwent PC insertion for
conditions other than ACC and to collect data on demographics,
comorbidities, PC management, PC related complications, length
of hospital stay and outcomes. Radiological reports and imaging
were used to determine PC route.
PC insertion was performed using a Seldinger technique by a
radiologist under local anaesthesia using either ultrasonography
or computed tomography (CT) for image guidance. Access to the
gallbladder was directed through a TH or TP route based on the
preference of the radiologist and anatomy of the patient. The
gallbladder was then aspirated to dryness and samples sent for
microbiological and cytological analysis.
Patients were followed for up to 12 months. PC complications
were included in the analysis if they required treatment or
resulted in the presentation of the patient at the emergency
department following discharge and included bile leak, infection
of PC insertion site (wound infection), bleeding from PC insertion
site (wound bleeding), PC insertion site pain, drain blockage,
accidental drain dislodgement or removal, and chronic fistula.
All bile leaks were confirmed by CT imaging. A drain was classed
as being ‘blocked’ if aspiration was not possible and CT imaging
confirmed a distended gallbladder, ‘dislodged’ if it remained in
the patient but was confirmed on imaging as being outside of
the gallbladder lumen.
A patient was classed as having no further treatment if they
recovered from the initial attack of ACC to the point of discharge
and did not require further hospital admission due to biliary
sepsis or drain-related complications, ERCP or did not progress
to cholecystectomy.
Statistical analysis was performed using IBM SPSS software
version 26 (SPSS Inc., Chicago, IL, USA). Categorical variables
were compared by the Fisher’s exact test. A two-tailed P value
of ≤0.05 was considered statistically significant.
RESULTS
A total of 78 patients underwent PC insertion at our centre
between November 2014 and June 2019. Of these procedures,
52 were treatment for ACC, the remainder being for acalculous
cholecystitis, malignancy and traumatic gallbladder perforation.
PC was performed by 39 different radiologists/radiology trainees
and placed via a TH route in 15 cases, TP route in 31 cases and for
6 cases it was not possible to determine the route retrospectively.
Sixty-seven percent (31/46) of patients were male and the mean
age at insertion was 73 (27–96) years (Table 1). The baseline
patient characteristics were similar with the exception of the
number of patients with cardiovascular disease in the TP group
versus the TH group (65% and 11%, respectively).
One patient was excluded from the outcome analysis in the
TP group because they underwent liver transplantation shortly
after PC insertion (14 days) during the same admission due to
deteriorating liver function.
Clinical outcomes are presented in Table 2. Follow-up ranged
from 6 to 12 months with the median follow-up times for each
group being 12 months. In summary, there were more PC related
complications in the TP group compared to the TH group (40%
versus 27%, P = 0.514) with 75% of these being due to the drain
becoming dislodged or falling out. The TP group also had a
greater proportion of patients being readmitted for biliary sepsis,
23% versus 13%, respectively (P = 0.695). However, a greater pro-
portion of the TH group progressed to ERCP or cholecystectomy
compared to the TP group, 33% versus 23% (P = 0.496) and 27%
versus 20% (P = 0.710), respectively. Mortality due to complica-
tions of biliary sepsis was the same for both groups (7%). In the
TH group, 40% of patients required no further treatment for their
ACC following PC insertion, compared to 27% in the TP group
(P = 0.497).
There was little difference in length of hospital stay between
the TH and TP groups, with the median being 20 days and
19 days, respectively. Considering PC management, the median
time to cholangiogram following PC insertion was 6 days in the
TH group and 9 days in the TP group. The median length of time
the PC drain was left in place before purposeful removal in the
TH group was 25 days compared to 34 days in the TP group.
DISCUSSION
Historically TH placement has been favoured in the literature
over TP despite a lack of comparative studies, the rationale for
this being a decreased risk of bile leak, catheter dislodgement,
and a decreased time to catheter track maturation [11]. The
largest review to date, including 371 patients over a 13-year
period, directly compared the two approaches in patients under-
going PC for any reason and reported no significant difference
between TH and TP approaches in complication rates or out-
comes [11]. It should be noted, however, that this Beland et al.
study included patients undergoing PC for any reason, a clinically
different population of patients compared to those included in
our case series who were treated specifically for ACC. Only 10%
of patients in the TH group and 10% of patients in the TP group
experienced their catheter falling out or becoming dislodged in
contrast to our findings of 7% and 30%, respectively. They also
reported bile leakage rates of 4% (TH group) and 3% (TP group);
in contrast to the 2 bile leaks seen in our review, both occurring
in the TP group (7%). Overall, the complication rate was notably
higher in the TP group compared to the TH group in our case
series.
A prospective study by Hatjidakis et al. concluded that only
2 weeks are required to develop a mature tract when the TH
access route is used compared to 3 weeks using the TP route
[12]. In our case series, the median length of time the PC drain
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Table 1. Patient characteristics
Overall (n = 46) Transhepatic (n = 15) Transperitoneal (n = 31)
Mean age (years) 73 (27–96) 72 (40–86) 74 (27–96)
Male 31 (67%) 10 (67%) 21 (68%)
Female 15 (33%) 5 (33%) 10 (32%)
Comorbidities:
Diabetes 6 (40%) 9 (29%)
Cardiovascular disease 8 (11%) 20 (65%)
Pulmonary disease 3 (20%) 11 (36%)
Chronic kidney disease 4 (27%) 6 (19%)
Immunosuppression 4 (27%) 4 (13%)
Premorbid function:
ADL independenta 9 (60%) 21 (68%)
ADL assisted 4 (27%) 8 (26%)
Fully dependent 2 (13%) 2 (7%)
aADL, activities of daily living.
Table 2. Patient outcomes
Overall (n = 45) Transhepatic (n = 15) Transperitoneal (n = 30)
Readmission for biliary sepsis 9 (18%) 2 (13%) 7 (23%)
Drain-related complicationsa: 16 (36%) 4 (27%) 12 (40%)
Bile leak 2 (4%) 0 (0%) 2 (7%)
Wound infection 1 (2%) 0 (0%) 1 (3%)
Wound bleeding 1 (2%) 1 (7%) 0 (0%)
Pain 1 (2%) 1 (7%) 0 (0%)
Drain blockage 1 (2%) 1 (7%) 0 (0%)
Drain dislodged 2 (4%) 0 (0%) 2 (7%)
Drain fell out 8 (18%) 1 (7%) 7 (23%)
Chronic fistula 1 (2%) 0 (0%) 1 (3%)
ERCPb 12 (27%) 5 (33%) 7 (23%)
Cholecystectomy: 10 (22%) 4 (27%) 6 (20%)
Elective 7 (16%) 3 (20%) 4 (13%)
Emergency 3 (6%) 1 (7%) 2 (7%)
Death due to complication of
biliary sepsis
3 (6%) 1 (7%) 2 (7%)
No further treatmentc 14 (31%) 6 (40%) 8 (27%)
aComplications were included if they required treatment or resulted in presentation at the emergency department following discharge.
bEndoscopic retrograde cholangiopancreatography.
cFurther treatment classified as additional admission due to biliary sepsis, drain complication, ERCP or cholecystectomy.
remained in situ was 25 days in the TH group compared to 34
days in the TP group.
The only randomized controlled trial comparing laparoscopic
cholecystectomy with PC in patients with ACC was published
in 2018 and reported that laparoscopic cholecystectomy was
superior to PC in the treatment of high-risk ACC patients. The
authors also concluded that PC was still an appropriate treat-
ment in patients with a strict contraindication for surgery. Of the
68 patients included in the PC group, 41% required emergency
readmission to hospital due to recurrent biliary disease [2]. This
is a higher rate than that seen in our case series (18%) and inter-
estingly we also observed a difference for this when comparing
the two approaches (23% in the TP group versus 13% in the
TH group). The CHOCOLATE trial also reported a higher rate of
progression to surgery (46%) compared to our case series (22%),
which may in part be due to the exclusion of critically ill patients
with an ‘acute physiology and chronic health disease classifica-
tion system II’ (APACHE II) score of ≥15 and those admitted to
the intensive care unit [2]. Of note, we also observed a difference
between approaches in the proportion of patients requiring no
further treatment for their ACC following PC insertion, with
a greater percentage being seen in the TH group (40% versus
27%), although the TH group was also more likely to progress
to surgery (27% versus 20%). Our overall mortality rate of 16%
is towards the lower end of the range (14%–30%) reported in the
literature for laparoscopic cholecystectomy in elderly or critically
ill patients with comorbid disease [4]. Our results, therefore,
suggest that PC is a valuable treatment option for ACC, not only
as a temporizing measure but, in selected cases, as definitive
treatment.
The limitations of this case series include the relatively small
sample size which likely impacted the achievement of statistical
significance. It is also possible that a patient may have presented
to another hospital for subsequent treatment, resulting in this
not being captured in the data. However, this is unlikely given
that all patients presented to our centre with their initial episode
of ACC (suggesting they would return for subsequent treatment)
and because all patients were followed up for 6–12 months,
during which time they were seen in outpatient clinic and all
relevant episodes recorded. Due to the retrospective design and
the fact that PC route was based on the preference of the radi-
ologist performing the procedure, it is possible that this could
4 S. Bennett et al.
have resulted in selection bias. However, given that all patients
undergoing PC for ACC at our tertiary centre over a 5-year period
were included, the authors feel this represents a meaningful
body of work in a subject area where PC route is much debated
and with limited prospective trials.
We believe our case series to be one of the largest to date
comparing the outcomes for patients undergoing PC via a TH
or TP approach specifically for the treatment of ACC. In our
experience, PC is an effective and relatively safe treatment for
ACC in cases where surgery is high risk or challenging both
to allow for surgical optimisation and as definitive treatment.
In the absence of more prospective trials, we prefer using a
TH route due to our observations of fewer complications, fewer
readmissions due to biliary sepsis and a reduction in the need
for further treatment compared to a TP route.
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